TMBR [AMEX]
Timber Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.27 Insider Own0.90% Shs Outstand64.75M Perf Week5.47%
Market Cap16.73M Forward P/E- EPS next Y- Insider Trans3.55% Shs Float63.59M Perf Month-4.30%
Income-11.90M PEG- EPS next Q- Inst Own4.30% Short Float3.18% Perf Quarter-9.30%
Sales0.90M P/S18.59 EPS this Y72.60% Inst Trans-0.25% Short Ratio1.83 Perf Half Y-41.66%
Book/sh0.17 P/B1.52 EPS next Y- ROA-106.20% Target Price1.50 Perf Year-78.64%
Cash/sh0.21 P/C1.20 EPS next 5Y- ROE-179.60% 52W Range0.23 - 1.41 Perf YTD-32.00%
Dividend- P/FCF- EPS past 5Y72.00% ROI-79.80% 52W High-81.67% Beta0.35
Dividend %- Quick Ratio3.60 Sales past 5Y54.70% Gross Margin- 52W Low12.06% ATR0.03
Employees5 Current Ratio3.60 Sales Q/Q85.60% Oper. Margin- RSI (14)43.72 Volatility9.24% 11.81%
OptionableNo Debt/Eq0.00 EPS Q/Q11.30% Profit Margin- Rel Volume0.47 Prev Close0.26
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.10M Price0.26
Recom2.00 SMA20-2.08% SMA50-15.98% SMA200-49.58% Volume521,012 Change-1.22%
May-12-22 04:10PM  
Apr-28-22 08:00AM  
Mar-31-22 05:44PM  
Mar-25-22 08:00AM  
Feb-28-22 07:30AM  
Feb-03-22 08:00AM  
Jan-06-22 08:00AM  
Dec-20-21 03:18PM  
Nov-17-21 04:18PM  
Nov-15-21 04:15PM  
Nov-09-21 04:05PM  
Nov-05-21 04:05PM  
Nov-03-21 08:00AM  
Nov-02-21 04:31PM  
Oct-07-21 09:11AM  
Oct-01-21 08:00AM  
Sep-10-21 05:58PM  
Aug-24-21 08:00AM  
Aug-10-21 08:00AM  
Jun-03-21 04:05PM  
May-26-21 04:05PM  
May-11-21 04:39PM  
Apr-28-21 08:00AM  
Apr-23-21 08:00AM  
Apr-02-21 04:05PM  
Mar-23-21 04:05PM  
Mar-17-21 08:00AM  
Mar-15-21 08:30AM  
Mar-05-21 08:30AM  
Jan-25-21 04:05PM  
Jan-12-21 04:22PM  
Dec-15-20 08:00AM  
Dec-10-20 08:30AM  
Dec-08-20 04:05PM  
Nov-20-20 09:05AM  
Nov-12-20 04:53PM  
Sep-15-20 08:00AM  
Sep-11-20 04:29PM  
04:05PM  
Aug-27-20 08:30AM  
Aug-19-20 04:10PM  
Aug-18-20 04:10PM  
Aug-06-20 02:01PM  
Jul-22-20 08:00AM  
Jul-01-20 08:00AM  
Jun-04-20 08:00AM  
Jun-03-20 08:00AM  
May-23-20 03:27PM  
Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-002, a proprietary topical formulation of rapamycin, which is in Phase 2b clinical trial for the treatment of facial angiofibroma in tuberous sclerosis complex, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs. It is also involved in the development of TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. In addition, the company engages in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. It has license agreement with AFT Pharmaceuticals Limited. The company was founded in 2019 and is headquartered in Basking Ridge, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rome ZacharyDirectorMar 04Option Exercise0.0179,32679379,326Apr 15 04:10 PM
Koconis JohnCEO & PresidentDec 15Buy0.3820,0007,68620,000Dec 16 04:23 PM
Mendelsohn AlanChief Medical OfficerNov 23Buy0.4710,0004,70010,000Nov 24 04:11 PM
Sitar Edward JDirectorNov 23Buy0.4615,0006,90015,000Nov 24 04:07 PM
TardiMed Sciences LLC10% OwnerSep 02Sale0.94225,000210,9603,508,567Sep 02 07:11 PM
TardiMed Sciences LLC10% OwnerSep 01Sale0.92150,500138,8663,733,567Sep 01 05:29 PM
TardiMed Sciences LLC10% OwnerAug 31Sale0.91150,000136,7403,884,067Sep 01 05:29 PM
TardiMed Sciences LLC10% OwnerAug 30Sale0.93100,00092,6604,034,067Sep 01 05:29 PM
TardiMed Sciences LLC10% OwnerAug 26Sale0.92100,00091,8404,134,067Aug 26 06:47 PM
TardiMed Sciences LLC10% OwnerAug 25Sale0.91100,00091,2604,234,067Aug 26 06:47 PM
TardiMed Sciences LLC10% OwnerAug 24Sale0.93100,00092,5304,334,067Aug 26 06:47 PM
TardiMed Sciences LLC10% OwnerAug 20Sale0.9150,00045,3954,434,067Aug 20 06:19 PM
TardiMed Sciences LLC10% OwnerAug 19Sale0.9550,00047,7004,484,067Aug 20 06:19 PM
TardiMed Sciences LLC10% OwnerAug 18Sale1.0075,00075,0754,534,067Aug 20 06:19 PM
TardiMed Sciences LLC10% OwnerJun 15Sale1.2628,45035,9244,609,067Jun 15 06:49 PM
TardiMed Sciences LLC10% OwnerJun 14Sale1.27146,465185,5574,637,517Jun 15 06:49 PM
TardiMed Sciences LLC10% OwnerJun 10Sale1.26185,229233,9264,783,982Jun 10 06:06 PM
TardiMed Sciences LLC10% OwnerJun 09Sale1.2796,481122,9074,969,211Jun 10 06:06 PM
TardiMed Sciences LLC10% OwnerJun 08Sale1.29305,540393,3835,065,692Jun 10 06:06 PM
TardiMed Sciences LLC10% OwnerJun 02Sale1.269,87912,4485,371,232Jun 02 05:57 PM
TardiMed Sciences LLC10% OwnerJun 01Sale1.268,67010,9525,381,111Jun 02 05:57 PM
TardiMed Sciences LLC10% OwnerMay 28Sale1.2747,73660,6205,389,781Jun 02 05:57 PM